Breast Neoplasm Female Clinical Trial
Official title:
Diagnosis Value of SEMA4C in Breast Cancer
Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.
Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Early diagnosis and access to optimum treatment are crucial to reduce mortality associated with breast cancer. Currently, mammography and breast ultrasonography are essential for the detection and diagnosis of disease, and breast magnetic resonance imaging is the choice to estimate the extent of disease and guide appropriate treatment. However, there is no robust biomarkers for early detection of breast cancer. Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. Therefore, this prospective project aims to assess the early diagnostic value of SEMA4C as a biomarker for breast cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03980626 -
Study on Physical Activity's Relationship With Cancer and Cognition
|
N/A | |
Completed |
NCT04329819 -
Satisfaction and QUality of Life After Breast REconstruction
|
||
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03900884 -
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT05042999 -
The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures
|
N/A | |
Recruiting |
NCT05075512 -
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Not yet recruiting |
NCT03629509 -
BEFORE Decision Aid Implementation Study
|
N/A | |
Completed |
NCT04811378 -
HaemoCerTM Application in Breast Cancer Surgery
|
N/A | |
Completed |
NCT03198442 -
Breast PET Feasibility
|
N/A | |
Not yet recruiting |
NCT05577442 -
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT04047823 -
Temperature and Injury in Radiotherapy Radiation Skin Injury
|
||
Recruiting |
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 | |
Recruiting |
NCT05027321 -
Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies
|
N/A | |
Active, not recruiting |
NCT04812652 -
Digitally Distributed Yoga for Women Treated for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03425838 -
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
|
Phase 3 | |
Completed |
NCT05473026 -
Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
|
N/A | |
Completed |
NCT04509063 -
Investigating Public Enthusiasm for Mammography Screening in Denmark
|
N/A | |
Recruiting |
NCT05711030 -
Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery
|
N/A | |
Suspended |
NCT03271853 -
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
|
N/A |